NasdaqGS:UTHRBiotechs
Stronger EPS, Ralinepag Progress, and Buybacks Might Change The Case For Investing In United Therapeutics (UTHR)
In the past week, United Therapeutics reported Q2 2026 results showing sales of US$783.3 million, a slight year-on-year dip, alongside higher net income of US$333 million and diluted EPS of US$7.27, while completing a US$1.50 billion buyback and highlighting strong phase 3 data plus an FDA filing for ralinepag in pulmonary arterial hypertension.
Beyond the quarterly numbers, the combination of robust ralinepag outcomes, New Drug Applications for ralinepag and nebulized Tyvaso, and meaningful...